Cancer Nanovaccines: Nanomaterials and Clinical Perspectives
Small · 2024
DOI: 10.1002/smll.202401631 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small, 2024. Verfasst von Nimeet Desai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, Telangana, 502285, India. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms, Nanostructures, Immunotherapy. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 453 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Foundation Ireland and Irish Research Council (SFI-IRC) pathway programme.
Abstract (Originalsprache)
Cancer nanovaccines represent a promising frontier in cancer immunotherapy, utilizing nanotechnology to augment traditional vaccine efficacy. This review comprehensively examines the current state‐of‐the‐art in cancer nanovaccine development, elucidating innovative strategies and technologies employed in their design. It explores both preclinical and clinical advancements, emphasizing key studies demonstrating their potential to elicit robust anti‐tumor immune responses. The study encompasses various facets, including integrating biomaterial‐based nanocarriers for antigen delivery, adjuvant selection, and the impact of nanoscale properties on vaccine performance. Detailed insights into the complex interplay between the tumor microenvironment and nanovaccine responses are provided, highlighting challenges and opportunities in optimizing therapeutic outcomes. Additionally, the study presents a thorough analysis of ongoing clinical trials, presenting a snapshot of the current clinical landscape. By curating the latest scientific findings and clinical developments, this study aims to serve as a comprehensive resource for researchers and clinicians engaged in advancing cancer immunotherapy. Integrating nanotechnology into vaccine design holds immense promise for revolutionizing cancer treatment paradigms, and this review provides a timely update on the evolving landscape of cancer nanovaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, Telangana, 502285, India.
- Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad, 380009, India.
- School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UK.
- Limerick Digital Cancer Research Centre (LDCRC), University of Limerick, Castletroy, Limerick, V94T9PX, Ireland.
- Department of Physics, Bernal Institute, Castletroy, Limerick, V94T9PX, Ireland.
- Nuffield Department of Women's & Reproductive Health, Medical Science Division, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK.
ORCID-Profile: Nimeet Desai, Vivek Chavda, Thakur Raghu Raj Singh, Lalitkumar K Vora
Förderung
- Science Foundation Ireland and Irish Research Council (SFI-IRC) pathway programme
Zitieren
APA
Desai, N., Chavda, V., Singh, T. R. R., Thorat, N. D., & Vora, L. K. (2024). Cancer Nanovaccines: Nanomaterials and Clinical Perspectives. Small. https://doi.org/10.1002/smll.202401631
Vancouver
Desai N, Chavda V, Singh TRR, Thorat ND, Vora LK. Cancer Nanovaccines: Nanomaterials and Clinical Perspectives. Small. 2024. doi:10.1002/smll.202401631
BibTeX
@article{Desai2024,
author = {Desai, Nimeet and Chavda, Vivek and Singh, Thakur Raghu Raj and Thorat, Nanasaheb D and Vora, Lalitkumar K},
title = {Cancer Nanovaccines: Nanomaterials and Clinical Perspectives},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202401631}
}
EUVIMED